This investigation of tuberculosis (TB) treatment regimens in 6 TB hospitals in China showed that only 18% of patients with new cases and 9% of patients with retreatment cases were prescribed standard TB treatment regimens. Adherence to treatment guidelines needs to be improved in TB hospitals to control multidrug-resistant TB in China.
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For several decades, the main drugs used to treat tuberculosis (TB) have essentially remained the same, and Mycobacterium tuberculosis strains that are resistant to these drugs have emerged in many areas. Although drug-resistant TB can emerge naturally, the widespread prevalence of drug resistance in TB strains is a man-made phenomenon caused by clinical and programmatic mismanagement of treatment [1, 2] . Adequate TB treatment regimens, as well as adequate compliance to these regimens, are essential to prevent further proliferation of drug-resistant TB [1] .
Multidrug-resistant TB (MDR-TB) has become a serious threat to TB control [3, 4] , and the emergence of extensively drug-resistant TB (XDR-TB) has further heightened this threat [5] [6] [7] . China is a country with a high burden of MDR-TB and XDR-TB [8] . On the basis of the national anti-TB drug resistance baseline surveillance in 2007, it is estimated that 120,000 new MDR-TB cases (including 9000 XDR-TB cases) emerge annually in China, accounting for 24% of the global burden of MDR-TB [3] .
In China, the National TB Control Program (NTP) is implemented directly through a network of TB centers, located throughout China, that possess the facilities to diagnose, treat, and manage TB according to the Stop TB strategy [10] . Unlike the TB centers, TB hospitals diagnose and treat TB but are not held to NTP guidelines, including directly observed treatment and follow-up. According to the national reporting system, 10% of all TB cases were reported by the TB hospitals. TB hospitals are obligated to refer patients with TB to TB centers after discharge from the hospital.
Recently, we showed that second-line TB drugs were widely available in health facilities throughout China and were especially common in TB hospitals, signifying the potential for the administration of improper treatment regimens [9] . However, the extent to which these drugs were used incorrectly in treatment regimens has not yet been reported. Therefore, we conducted an investigation of TB treatment regimens used in TB hospitals in China.
METHODS
We categorized all provinces into 3 regions: eastern, middle, and western regions. In each region, 2 provinces with relatively high human resource capacities at the provincial TB center and consent to participate in the study were randomly selected, and only the provincial TB hospital was selected for inclusion.
The medical records of patients with TB in the 6 selected TB hospitals were compiled and reviewed. Field investigations were conducted in July 2009. Staff from the National TB Center and Provincial TB Center collected information on treatment history, treatment regimens, and drug susceptibility testing (DST) results from the medical records for all patients with TB in the second quarter of 2009 in each of the TB hospitals.
NTP treatment regimens for new smear-positive patients prescribe 2 months of isoniazid (H), rifampicin (R), pyrazinamide (Z), and ethambutol (E)-streptomycin (S) followed by 4 months of H and R daily or 3 times weekly (2HRZE[S]/ 4HR, 2H 3 R 3 Z 3 E 3 [S]/4H 3 R 3 ). Patients who had previously received at least 1 month of TB treatment (ie, retreatment patients) received 2HRZES/6HRE, 2H 3 R 3 Z 3 E 3 S 3 /6H 3 R 3 E 3 , 3HRZE/6HRE, or 3H 3 R 3 Z 3 E 3 /6H 3 R 3 E 3 [11] . The China standardized treatment regimen for new smear-positive TB cases is identical to the international standard regimen [1] . For retreatment patients with TB, the international standard regimen is 2HRZES/1HRZE/5HRE, and bacteria cultures and DSTs are strongly recommended for retreatment patients [1] .
Data were double entered in EpiData software, version 3.1 (The EpiData Association), and discrepancies were checked against the raw data. Analysis was performed using SPSS software, version 13.0 (SPSS). This study was approved by the Chinese Managing Committee for TB Operational Research.
RESULTS
In the 6 TB hospitals, 828 patients with TB were admitted and treated in the second quarter of 2009. Treatment history and TB treatment drugs were clearly written down in all medical records. Among the patients with TB who were admitted, 518 (62.6%) were male and 310 (37.4%) were female; the mean age was 43 years (range, 3-88 years); 211 (25.5%) of the patients were from the eastern region, 272 (32.9%) were from the middle region, and 345 (41.6 %)were from the western region of China.
Sixty different treatment regimens were used to treat the 828 patients with TB in the TB hospitals. Among these, 541 (65.3%) had new cases that were treated with 46 different treatment regimens, 287 (34.7%) had retreatment cases (including 19 [6.6%] who had MDR-TB cases) that were treated with 55 different treatment regimens. Only 120 (14.8%) of the patients, including 95 (17.6%) with new cases and 25 (9.3%) with retreatment cases, were prescribed treatment regimens recommended by the China NTP/World Health Organization (WHO) TB treatment guidelines [1, 11] . Other patients with TB were prescribed regimens that were inconsistent with NTP and WHO standards (Table 1) . At least 1 second-line drug was used in treatment regimens prescribed to 410 (75.8%) of the patients with new cases and 243 (84.6%) of the patients with retreatment cases. Among new cases, the most commonly used regimen was 4 first-line drugs, which was followed by 4 first-line drugs plus fluoroquinolone and 3 first-line drugs plus injection drugs. Four first-line drugs was also most frequently used among retreatment cases; 3 first-line drugs plus fluoroquinolone ranked second, followed by the use of 3 first-line drugs only. In general, the most commonly used second-line drug was fluoroquinolone in the eastern and middle regions and injectable second-line drugs in the western region. (Table 2) . Among 19 MDR-TB cases, 16 (84%) were resistant to 1 first-line drug besides H and R, and 3 were resistant to 4 different first-line drugs. Eight (42.1%) cases were resistant only to levofloxacin, 1 (5.3%) was resistant only to amikacin, and 3 (15.8%) were resistant to both levofloxacin and amikacin and classified as XDR-TB. Among 19 treatment regimens for MDR-TB, 2 only included first-line drugs, only 1 case was treated with a regimen fulfilling the criteria for an appropriate individualized MDR-TB regimen [1, 2] . Among the regimens prescribed for the 54 non-MDRTB cases, most (83.4%) included second-line drugs.
The standard treatment regimens were used more often in the eastern region. Among new cases, a standard regimen was prescribed for 38% (57 of 151) of the cases in the eastern region,compared with 14% (20 of 140) in the middle and 7% (18 of 250) in the western regions (v2562.0; P,.001). Among retreatment cases, a standard regimen was prescribed for 24% (12 of 50) of the cases in the eastern region,compared with 8% (10 of 123) of the cases in the middle and 3% (3 of 195) of the cases in the western regions (v2517.2; P,.001). Second-line drugs were prescribed more frequently in the western region than in the other 2 regions (v2563.9; P,.001).
DISCUSSION
This study showed that only a small proportion of TB cases in Chinese TB hospitals were treated with appropriate NTP/WHO treatment regimens [1, 11] , while only one proven MDR-TB case was treated with an appropriate individual regimen in accordance with DST results [1, 2] . Adherence to standard NTP/ WHO guidelines was higher in the more developed eastern region, compared with the less developed middle and western regions.
Second-line drugs, including both injection drugs and fluoroquinolones, were commonly used to treat TB cases. If not combined properly with other drugs, this poses a risk for the development of drug resistance, including MDR-TB and XDR-TB. Almost one-quarter of the treatment regimens for new and retreatment cases included 4 first-line drugs and at least 1 second-line drug. Extra second-line drugs may cause more adverse effects, induce patient discomfort, and lead to treatment default or irregular drug intake. Almost all patients with MDR-TB cases were prescribed inappropriate regimens that may not lead to successful treatment and may even expand drug resistance.
Our findings revealed widespread nonadherence to WHO/ NTP guidelines in TB hospitals in China. A serious threat is the potential expansion of TB drug resistance as the result of inappropriate administration of treatment regimens [1] . The mismanagement of TB treatment adds an extra burden not only to the patients who either receive inappropriate regimens that decrease the chance of cure and/or must pay for unnecessary and expensive second-line drugs but also to the greater community because of the increased chances of development of drugresistant TB and its transmission. In our study, only 73 (8.8%) of the patients underwent drug susceptibility testing. Considering the high prevalence of MDR-TB in China, expansion of DST alongside more-standardized treatment regimens should be a top priority.
There are several limitations in this study. Most of the patients admitted to TB hospitals are treated for a relatively short amount of time (1 month). Thus, our data only represent TB treatment regimens at the start of treatment, and the medical records did not contain additional information after hospital discharge. Therefore, the study aims to merely point out the prevalent deviation from standard TB treatment protocols in TB hospitals. This study also focused on the specific combinations of TB drugs used for treatment and did not collect data on the dosages. Because only 6 TB hospitals were investigated, the reported results may not be representative of all TB hospitals in China. MDR-TB and XDR-TB currently present one of the major challenges in TB control in China [3, 12] . Our findings show that incorrect TB treatment regimens are prevalent in Chinese TB hospitals, heightening the risk for the development of drugresistant TB. Despite the fact that TB hospitals have better equipment and more well-trained medical staff than the TB centers, there is still a pervasive lack of adherence to accepted and established TB treatment protocols [11] . TB hospitals should be integrated into the NTP, and a better mechanism for collaboration between TB hospitals and TB Control Centers should be developed to more effectively address the challenges of TB control in China.
